Sort   by:  
 Page size 
UnknownOral idasanutlin in patients with polycythemia vera.
Not available
S-EPMC6688433 | biostudies-literature
UnknownNeutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera.
Not available
S-EPMC8831521 | biostudies-literature
UnknownEvaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial.
Not available
S-EPMC4382667 | biostudies-literature
UnknownPegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea.
Not available
S-EPMC6839950 | biostudies-literature
UnknownJAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis.
Not available
S-EPMC8665926 | biostudies-literature
UnknownA randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia.
Not available
S-EPMC9101248 | biostudies-literature
UnknownThe MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study.
Not available
S-EPMC8864654 | biostudies-literature
UnknownA phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis.
Not available
S-EPMC5210237 | biostudies-literature
UnknownFirst-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer.
Not available
S-EPMC5648176 | biostudies-literature
UnknownBeyond Post hoc Explanations: A Comprehensive Framework for Accountable AI in Medical Imaging Through Transparency, Interpretability, and Explainability
Not available
S-EPMC12383817 | biostudies-literature
Sort   by:  
 Page size